CA2046014A1 - Reduction or prevention of skin irritation by drugs - Google Patents
Reduction or prevention of skin irritation by drugsInfo
- Publication number
- CA2046014A1 CA2046014A1 CA002046014A CA2046014A CA2046014A1 CA 2046014 A1 CA2046014 A1 CA 2046014A1 CA 002046014 A CA002046014 A CA 002046014A CA 2046014 A CA2046014 A CA 2046014A CA 2046014 A1 CA2046014 A1 CA 2046014A1
- Authority
- CA
- Canada
- Prior art keywords
- drug
- irritation
- skin
- mucosa
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Packaging For Recording Disks (AREA)
- Passenger Equipment (AREA)
- Steroid Compounds (AREA)
Abstract
The present invention provides a method of reducing or preventing skin irritation of a weak base drug by inhibiting the accumulation of the drug in the lysosomes. The drug is irritating to humans, i.e., the drug is susceptible to inducing skin or mucosa irritation in a human when the drug is transdermally administered to the human at a therapeutically effective rate. Irritation reduction or prevention is induced by coadministering to the skin or mucosa of the human:
(a) a therapeutically effective amount of a weak base drug which is irritating to humans, at a therapeutically effective rate over a predetermined period of time; and (b) an effective amount of an agent capable of inhibiting the lysosomal uptake of the drug to reduce or prevent irritation to the skin or mucosa.
(a) a therapeutically effective amount of a weak base drug which is irritating to humans, at a therapeutically effective rate over a predetermined period of time; and (b) an effective amount of an agent capable of inhibiting the lysosomal uptake of the drug to reduce or prevent irritation to the skin or mucosa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/549,584 | 1990-07-06 | ||
US07/549,584 US5130139A (en) | 1990-07-06 | 1990-07-06 | Reduction or prevention of skin irritation by drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2046014A1 true CA2046014A1 (en) | 1992-01-07 |
CA2046014C CA2046014C (en) | 2003-05-20 |
Family
ID=24193593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002046014A Expired - Fee Related CA2046014C (en) | 1990-07-06 | 1991-06-28 | Reduction or prevention of skin irritation by drugs |
Country Status (18)
Country | Link |
---|---|
US (1) | US5130139A (en) |
EP (1) | EP0538302B1 (en) |
JP (1) | JP3224814B2 (en) |
AT (1) | ATE121627T1 (en) |
AU (1) | AU641787B2 (en) |
CA (1) | CA2046014C (en) |
DE (1) | DE69109292T2 (en) |
DK (1) | DK0538302T3 (en) |
ES (1) | ES2071322T3 (en) |
FI (1) | FI930038A0 (en) |
GR (1) | GR3015934T3 (en) |
IE (1) | IE74152B1 (en) |
MX (1) | MX9100042A (en) |
NO (1) | NO925038L (en) |
NZ (1) | NZ238804A (en) |
PT (1) | PT98177B (en) |
WO (1) | WO1992000746A1 (en) |
ZA (1) | ZA915067B (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5417974A (en) * | 1991-11-08 | 1995-05-23 | The Green Cross Corporation | Biocidal self-adhesive and process for producing the same, as well as self-adhesive and application thereof |
US5843979A (en) * | 1993-02-25 | 1998-12-01 | Bristol-Myers Squibb Company | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity |
IL109036A (en) * | 1993-03-19 | 1998-12-27 | Cellegy Pharamaceuticals Inc | Compositions for disrupting the epithelial barrier function and use of agents for preparing such compositions |
US6190894B1 (en) | 1993-03-19 | 2001-02-20 | The Regents Of The University Of California | Method and compositions for disrupting the epithelial barrier function |
US5451407A (en) * | 1993-06-21 | 1995-09-19 | Alza Corporation | Reduction or prevention of skin irritation or sensitization during transdermal administration of a irritating or sensitizing drug |
WO1995026782A1 (en) | 1994-03-30 | 1995-10-12 | Alza Corporation | Reduction of skin irritation during electrotransport delivery |
WO1995034262A1 (en) * | 1994-06-16 | 1995-12-21 | Department Of The Army, Us Government | Transdermal treatment of malaria |
US5686100A (en) * | 1994-11-22 | 1997-11-11 | E.R. Squibb & Sons, Inc. | Prophylactic and therapeutic treatment of skin sensitization and irritation |
WO1997047355A1 (en) * | 1996-06-12 | 1997-12-18 | Alza Corporation | Reduction of skin sensitization in electrotransport drug delivery |
US6512010B1 (en) * | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
US5981168A (en) * | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
US6699497B1 (en) * | 1998-07-24 | 2004-03-02 | Alza Corporation | Formulations for the transdermal administration of fenoldopam |
US20040258742A1 (en) * | 2003-04-11 | 2004-12-23 | Van Osdol William Woodson | Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines |
AU2005284908B2 (en) | 2004-09-13 | 2011-12-08 | Morningside Venture Investments Limited | Biosynchronous transdermal drug delivery |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US20070042026A1 (en) * | 2005-03-17 | 2007-02-22 | Wille John J | Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions |
WO2006127905A2 (en) | 2005-05-24 | 2006-11-30 | Chrono Therapeutics, Inc. | Portable drug delivery device |
WO2008092003A2 (en) | 2007-01-25 | 2008-07-31 | Honda Motor Co., Ltd. | Vehicle systems control for improving stability |
WO2013006643A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
WO2014121342A1 (en) * | 2013-02-08 | 2014-08-14 | Luoda Pharma Pty Limited | Methods of treating topical microbial infections |
WO2016123406A1 (en) | 2015-01-28 | 2016-08-04 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
CA2977814A1 (en) | 2015-03-12 | 2016-09-15 | Chrono Therapeutics Inc. | Craving input and support system |
EP3565617A1 (en) | 2017-01-06 | 2019-11-13 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
CA3101966A1 (en) | 2018-05-29 | 2019-12-05 | Morningside Venture Investments Limited | Drug delivery methods and systems |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3598122A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3991755A (en) * | 1973-07-27 | 1976-11-16 | Medicon, Inc. | Iontophoresis apparatus for applying local anesthetics |
US4274420A (en) * | 1975-11-25 | 1981-06-23 | Lectec Corporation | Monitoring and stimulation electrode |
US4141359A (en) * | 1976-08-16 | 1979-02-27 | University Of Utah | Epidermal iontophoresis device |
US4325367A (en) * | 1977-06-13 | 1982-04-20 | Robert Tapper | Iontophoretic treatment apparatus |
US4250878A (en) * | 1978-11-22 | 1981-02-17 | Motion Control, Inc. | Non-invasive chemical species delivery apparatus and method |
CA1153427A (en) * | 1978-12-11 | 1983-09-06 | Patrick T. Cahalan | Tape electrode |
JPS56501274A (en) * | 1979-10-10 | 1981-09-10 | ||
US4286592A (en) * | 1980-02-04 | 1981-09-01 | Alza Corporation | Therapeutic system for administering drugs to the skin |
US4314557A (en) * | 1980-05-19 | 1982-02-09 | Alza Corporation | Dissolution controlled active agent dispenser |
US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
JPS5810066A (en) * | 1981-07-10 | 1983-01-20 | 株式会社アドバンス | Plaster structure for ion tofuorese |
US4419092A (en) * | 1981-11-06 | 1983-12-06 | Motion Control, Inc. | Iontophoretic electrode structure |
GB2124485B (en) * | 1982-08-04 | 1986-06-04 | Michael A Levy | Penetrating topical medicament |
US4559222A (en) * | 1983-05-04 | 1985-12-17 | Alza Corporation | Matrix composition for transdermal therapeutic system |
US4557723A (en) * | 1983-08-18 | 1985-12-10 | Drug Delivery Systems Inc. | Applicator for the non-invasive transcutaneous delivery of medicament |
US4640689A (en) * | 1983-08-18 | 1987-02-03 | Drug Delivery Systems Inc. | Transdermal drug applicator and electrodes therefor |
US4708716A (en) * | 1983-08-18 | 1987-11-24 | Drug Delivery Systems Inc. | Transdermal drug applicator |
US4573995A (en) * | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
US4702732A (en) * | 1984-12-24 | 1987-10-27 | Trustees Of Boston University | Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands |
FR2605221B1 (en) * | 1986-10-20 | 1989-09-01 | Sanofi Sa | PHARMACEUTICAL OR VETERINARY COMPOSITIONS CONTAINING DE (HYDROXYMETHYL) -25 DEOXY-25 OXO-25 MONENSINE |
AU610839B2 (en) * | 1986-11-07 | 1991-05-30 | Purepac, Inc | Transdermal administration of amines |
US4983395A (en) * | 1987-11-12 | 1991-01-08 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US4885154A (en) * | 1988-03-01 | 1989-12-05 | Alza Corporation | Method for reducing sensitization or irritation in transdermal drug delivery and means therefor |
US4855294A (en) * | 1988-09-06 | 1989-08-08 | Theratech, Inc. | Method for reducing skin irritation associated with drug/penetration enhancer compositions |
US4908213A (en) * | 1989-02-21 | 1990-03-13 | Schering Corporation | Transdermal delivery of nicotine |
JPH04506072A (en) * | 1989-06-19 | 1992-10-22 | ザ・ウエルカム・ファウンデーション・リミテッド | Medicines useful in cancer treatment and having antihistamine properties |
-
1990
- 1990-07-06 US US07/549,584 patent/US5130139A/en not_active Expired - Lifetime
-
1991
- 1991-06-28 CA CA002046014A patent/CA2046014C/en not_active Expired - Fee Related
- 1991-07-01 NZ NZ238804A patent/NZ238804A/en unknown
- 1991-07-01 PT PT98177A patent/PT98177B/en not_active IP Right Cessation
- 1991-07-01 ZA ZA915067A patent/ZA915067B/en unknown
- 1991-07-01 MX MX9100042A patent/MX9100042A/en not_active IP Right Cessation
- 1991-07-01 AT AT91912369T patent/ATE121627T1/en not_active IP Right Cessation
- 1991-07-01 EP EP91912369A patent/EP0538302B1/en not_active Expired - Lifetime
- 1991-07-01 WO PCT/US1991/004685 patent/WO1992000746A1/en active IP Right Grant
- 1991-07-01 AU AU81046/91A patent/AU641787B2/en not_active Ceased
- 1991-07-01 DE DE69109292T patent/DE69109292T2/en not_active Expired - Fee Related
- 1991-07-01 IE IE229491A patent/IE74152B1/en not_active IP Right Cessation
- 1991-07-01 DK DK91912369.5T patent/DK0538302T3/en active
- 1991-07-01 ES ES91912369T patent/ES2071322T3/en not_active Expired - Lifetime
- 1991-07-01 JP JP51195691A patent/JP3224814B2/en not_active Expired - Fee Related
-
1992
- 1992-12-30 NO NO92925038A patent/NO925038L/en unknown
-
1993
- 1993-01-05 FI FI930038A patent/FI930038A0/en not_active Application Discontinuation
-
1995
- 1995-04-27 GR GR940403851T patent/GR3015934T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
PT98177A (en) | 1993-08-31 |
JP3224814B2 (en) | 2001-11-05 |
DE69109292D1 (en) | 1995-06-01 |
MX9100042A (en) | 1992-02-28 |
DK0538302T3 (en) | 1995-09-18 |
NO925038L (en) | 1993-01-06 |
EP0538302B1 (en) | 1995-04-26 |
FI930038A (en) | 1993-01-05 |
US5130139A (en) | 1992-07-14 |
IE912294A1 (en) | 1992-01-15 |
ZA915067B (en) | 1992-04-29 |
JPH05508643A (en) | 1993-12-02 |
DE69109292T2 (en) | 1995-08-31 |
EP0538302A1 (en) | 1993-04-28 |
NZ238804A (en) | 1992-08-26 |
IE74152B1 (en) | 1997-07-02 |
ATE121627T1 (en) | 1995-05-15 |
PT98177B (en) | 1998-12-31 |
AU641787B2 (en) | 1993-09-30 |
CA2046014C (en) | 2003-05-20 |
ES2071322T3 (en) | 1995-06-16 |
GR3015934T3 (en) | 1995-07-31 |
AU8104691A (en) | 1992-02-04 |
FI930038A0 (en) | 1993-01-05 |
NO925038D0 (en) | 1992-12-30 |
WO1992000746A1 (en) | 1992-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2046014A1 (en) | Reduction or prevention of skin irritation by drugs | |
WO1992002234A3 (en) | Reduction or prevention of sensitization to drugs | |
NZ508526A (en) | Opioid formulations for treating pain | |
GB2264640B (en) | Microcrystalline cellulose spheroids comprising hydromorphone and a sugar | |
CA2184242A1 (en) | Drug Targeting System, Method for Preparing Same and Its Use | |
GB9401891D0 (en) | Therapeutic agents | |
EP0962225A3 (en) | Use of phentolamine for the manufacture of a medicament for the treatment of erectile dysfunction | |
EE9700132A (en) | An inhalation device, a method of spraying a pharmaceutically active agent, and a method of administering a dose of a pharmaceutically active agent | |
CA2126611A1 (en) | Opiod Formulations Having Extended Controlled Release | |
HUP9801591A3 (en) | Use of nitric oxide-releasing agents for producing pharmaceutical composition to treat impotency, and delivery device dosage of nitric oxide | |
GR3032523T3 (en) | Therapeutic preparation for the transdermal administration of active substances | |
WO1994008551A3 (en) | Pharmaceutical compositions and methods for treating cold symptoms | |
CA2299361A1 (en) | Use of consensus interferon in combination with il-1 receptor antagonist for treatment of patients afflicted with multiple sclerosis | |
CA2061270A1 (en) | Method and Composition for Treating Reperfusion Injury | |
NO952906L (en) | Pharmaceutical formulation for the treatment of nicotine addiction | |
AU2313297A (en) | Transdermally administered dextromethorphan as antitussive agent | |
MY124465A (en) | Reduction of infarct volume using citicoline | |
CA2156481A1 (en) | 5-ht2 receptor antagonist compositions useful in treating venous conditions | |
EP0799618A3 (en) | Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer | |
WO2001041771A3 (en) | Transdermal system containing acetylsalicylic acid for treatment of migraine | |
EP1264601A3 (en) | Treatment of a coronary condition by delivery of therapeutics to the pericardial space | |
CA2235617A1 (en) | Therapeutic preparation for the transdermal administration of active substances | |
Sustained-release et al. | Antiseptic: see CHLORHEXIDINE | |
CA2288966A1 (en) | Preventives and remedies for ulcerous colitis and/or crohn's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |